FDA Advisory Panel CoI Statements Should Be More Transparent – NEJM
This article was originally published in The Gray Sheet
Executive Summary
FDA may need to change its conflict-of-interest policies for advisory panels, a column in the July 14 New England Journal of Medicine proposes
You may also be interested in...
Women’s Groups Urge Congress To Review Silicone Implant Panel Meeting
The Senate HELP Committee is reviewing a letter from six women's groups requesting a congressional oversight investigation into the recent FDA panel meeting on silicone breast implants
FDA CoI Policies For Advisory Committees Viewed As Fair, Credible – Study
Advisory committee members and meeting attendees perceive FDA's management of real or potential conflicts of interest among committee members as generally fair and credible, a 1study funded by the Joint Institute for Food Safety & Applied Nutrition says
Anti-Silicone Implant Media Campaign, Rally Planned By Consumer Groups
A petition from Public Citizen appears to have persuaded FDA to disclose the General & Plastic Surgery Devices Panel roster nearly two weeks before the panel's review of a silicone gel breast implant premarket application